Small Bowel Carcinoid Tumor Clinical Trial
Official title:
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
This research study is designed to evaluate a type of scan called Ga-68-DOTA-TOC positron emission tomography (PET) scanning as a way of assessing carcinoid tumors.
This research study is a Pilot Study, which is the first time investigators are examining
this study intervention.
Many patients who are diagnosed with carcinoid tumor undergo treatment with long acting
release (LAR) octreotide. It is presently standard for all patients to receive equal doses of
octreotide. However, the response to the treatment with the same dose of medication may vary
substantially from one person to another. This study uses a novel form of PET/MR imaging to
try and better understand how to treat carcinoid tumors, and may in the future allow doctors
to tailor treatment dosing based on PET/MR findings and select the right drug dose for an
individual person. It is important to note that the participant method of treatment and the
dose of the participant medication (Octreotide LAR) will not change in this study.
The imaging technique used in this study is called Ga-68-DOTA-TOC PET/MR scanning.
Ga-68-DOTA-TOC is a radioactive tracer that is given by vein to participants before PET
scanning. The scanner then detects radioactivity from the tracer that is attached to cells
within the body and uses this information to create images (pictures) on a computer screen
that can then be analyzed.
These types of scans are investigational. "Investigational", meaning that the scans are still
being studied and that research doctors are trying to find out more about them. It also means
that the FDA (U.S. Food and Drug Administration) has not approved these types of PET scans
for this type of cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05670574 -
Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors
|
N/A |